T1	Participants 84 106	advanced breast cancer
T2	Participants 184 220	60 women with advanced breast cancer
T3	Participants 485 677	All patients were post-menopausal, previously untreated with hormone therapy, and with tumor receptor status determined immediately before randomization; all had objectively evaluable lesions.
